2/23/2021 8:15:48 AM
Soliton Says RAP Treatment Reduces Effects Of Liver Fibrosis By 42% In Animal Study
2/1/2021 8:08:11 AM
Soliton Says FDA Cleared Rapid Acoustic Pulse Technology For Short-term Improvement In Appearance Of Cellulite
1/26/2021 8:28:14 AM
Soliton Enters Collaboration With US Navy To Conduct Proof-of-Concept Study For Fibrotic Scars
12/30/2020 8:04:53 AM
Soliton Appoints Sean Shapiro As VP Of Sales
11/12/2020 7:49:27 AM
Soliton Q3 Net Loss $3.6 Mln Or $0.17/shr Vs. Net Loss $4.3 Mln Or $0.27/shr Last Year
11/2/2020 8:08:43 AM
Soliton Appoints Aesthetic Executive Brad Hauser As President & CEO
10/22/2020 8:17:52 AM
Soliton Appoints Niquette Hunt To Its Board
8/26/2020 8:05:58 AM
Soliton Initiates New Tooling Production Process For Improved Cartridge In RAP Device
8/13/2020 8:24:16 AM
Soliton Completes Design Process For Advanced Handpiece And Cartridge For Its Rapid Acoustic Pulse Device
8/11/2020 7:35:28 AM
Soliton Q2 Net Loss $3.1 Mln Or $0.19/shr Vs. Net Loss $3.0 Mln Or $0.20/shr Last Year
8/5/2020 8:07:22 AM
Soliton Appoints Sachin Shridharani To Scientific Advisory Board
7/15/2020 8:04:52 AM
Soliton Receives FDA Acceptance For 510(k) Application
7/1/2020 8:07:04 AM
Soliton Files 510(k) With FDA For RAP Device For Reduction Of Cellulite
6/26/2020 9:26:39 AM
Soliton Announces Pricing Of Underwritten Public Offering Of 4.22 Mln Shares At $8.30/shr